期刊文献+

小剂量多巴胺治疗重度卵巢过度刺激综合征的临床效果分析 被引量:4

Clinical analysis of low dose dopamine in the treatment of severe ovarian hyperstimulation syndrome
下载PDF
导出
摘要 目的:探讨小剂量多巴胺治疗重度卵巢过度刺激综合征的临床效果。方法:选取2015年6月~2017年3月我院收治的66例重度卵巢过度刺激综合征患者,随机分为观察组和对照组,对照组采取白蛋白治疗,观察组在对照组治疗基础上联合小剂量多巴胺进行治疗。结果:观察组在治疗后2d和治疗后5d时,HCT均明显低于对照组(P<0.05);观察组比对照组尿量恢复时间短(P<0.05)。结论:应用小剂量多巴胺对重度卵巢过度刺激综合征开展治疗,可使症状得到迅速缓解,缩短病程,减少并发症,值得临床上推广。 Objective:To explore the clinical effect of low dose dopamine on severe ovarian hyperstimulation syndrome.Methods:66 patients with severe ovarian hyperstimulation syndrome in June 2015~March 2017were selected as theresearch objects and randomly divided into the control group and the observation group.The patients in the control group were treated .with albumin treatments.The patients in the observation group were treated with the low dose dopamine treatment,as well as the treatment in control group.Results: The hematocrit of observation group was obviously lower than control groupIn in two days after treatment,as well as in five days after treatment(P<0.05);the urine volume recovery time in observation group were significantly shorter than thosein,control group (P<0.05). Conclusion:Low dose dopamine can quickly improve ,the symptoms,shorten the course of disease,reduce complications of OHSS, suggesting it should be worth popularizing in clinical application.
作者 王亚丽 张祎 Wang Yali;Zhang Yi(Luohe Second People's Hospital,Henan 462000,Luohe,China)
出处 《北方药学》 2019年第1期23-23,共1页 Journal of North Pharmacy
关键词 小剂量多巴胺 卵巢过度刺激综合征 红细胞比容 尿量 效果 Low dose dopamine Severe ovarianhyperstimulation syndrome Hematocrit(HCT) Urine volume Effect
  • 相关文献

参考文献3

二级参考文献36

  • 1Nastri C O, Ferriani R A, Rocha I A, et al. Ovarian hypers- tirnulation syndrome: pathophysiology and prevention [J]. J Assist Reprod Gen, 2010, 27(2-3): 121-128.
  • 2Rollene N L, Amols M H, Hudson S B, et al. Treatment ofo varian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist : a case series[J]. Fertility Sterility, 2009, 92(3):116915-116917.
  • 3Shaltout A, Shohyab A, Youssef M A. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles: A randomized controlled study[J]. Euro J Obstet Gynecol Reprod Biol, 2012, 165(2): 254-258.
  • 4Kalampokas T, Creatsas G, Kalampokas E. Cabergofine as treatment of ovarian hyperstimulation syndrome: a review[J]. GynecoI Endocrinol, 2013, 29(2): 98-100.
  • 5Ferraretti A P, Gianaroli L, Diotallevi I., et ai. Dopamine treatment for severe ovarian hyperstimulation syndrome [J]. Human Reprod , 1992, 7(2): 180-183.
  • 6Alvarez C, Marti Bonmati L, Novella-Maestre E, et al. Dopa- mine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction[J]. J Clin Endocrlnol Metabolism, 2007, 92(8): 2931-2937.
  • 7Vanrell J A, Balasch J. Prolactin in the evaluation of luteal phase in infertility[J]. Fertility Sterility, 1983, 39(1) : 30-33.
  • 8Alvarez C, Alonso-Muriel I, Garcia G, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syn- drome in women undergoing assisted reproduction treatment: a pilot study[J]. HumanReprod, 2007, 22(12): 3210-3214.
  • 9Carizza C, Abdelmassih V, Abdeimassih S, et ai. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study[J]. Reprod Bio Med Online, 2008, 17(6): 751-755.
  • 10Busso C, Ferndndez-Sdnchez M, Garcia Velasco J A, et al. The non ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF pa- tients: a randomized, double-blind, placebo-controlled trial [J]. HumanReprod , 2010, 25(4): 995 1004.

共引文献19

同被引文献54

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部